In Turkey over 10 thousand

In the hospital of the Faculty of Medical Faculty of the University of GAZI in Ankara, more than 10 thousand oncomials received hope for recovery thanks to the modern gamma-knife radiation therapy.

Gamma-Nozh is used in the treatment of patients not only with brain tumors, but also a number of mental illness. Since 2004, Gamma-Nozh has been used in Turkey, patients receive free treatment. Gamma-Nozh is a unique device of radiosurgical effects that allows you to treat brain tumors without surgical intervention.

The University teacher, Professor Hakan Ammaz told Anadolu that the Gamma-Nozh tool has established itself as a reliable and safe treatment for treatment, has been widely recognized in the last 20-30 years. It allows you to focus the rays directly on the tumor.

“We are the second institution in Turkey, where the Gamma -Nozh apparatus is used. Over the past 19 years, more than 10 thousand people have received treatment. Patients receive treatment for free, due to state resources,” he said.

Ammaz emphasized that the method was successful in the treatment of brain tumors, cerebrovascular diseases that cause bleeding, as well as tumors located deep and for which surgical intervention, some mental illness is not suitable. “Most of the patients we treat with the help of” gamma-no “are people with benign or malignant tumors and vascular diseases. In addition, the method is effective in the treatment of some enhancing mental disorders, for example, obsessive-compulsive. In these cases, a resolution of a psychiatric departments, ”he said.

The professor emphasized that the “gamma-knife” is an effective auxiliary method of treatment for surgical intervention. It is not suitable for the treatment of certain types of tumors, especially effective for tumors of small and medium size.

“Gamma-Nozh” mainly allows us to control the tumors. It is not always possible to completely cure the tumor, but it is very important to prevent tumor growth and protect patients from death. The device provides 90-95 percent success with benign tumors, this indicator can decrease to 80-75 percent with malignant tumors, ”he said.